FiercePharmaOriginal article
{"a":[{"_":"J&J firms up Caplyta's 1st phase 3 win in bipolar-associated manic episodes","$":{"href":"/pharma/jj-firms-caplytas-1st-phase-3-win-bipolar-associated-manic-episodes","hreflang":"en"}}]}
Phase 3positiveCaplytaPositive
AI Analysis
Summary
Johnson & Johnson's Caplyta, acquired through its $14.6 billion acquisition of Intra-Cellular Therapies, has achieved positive Phase 3 results for bipolar-associated manic episodes, supporting a potential label expansion for the atypical antipsychotic.
Clinical Trial Data
Phase
3
Primary Endpoint
Met
Outcome Details
Phase 3 trial passed for bipolar-associated manic episodes indication
Importance:7/10
Sentiment:
0.80
Phase 3 successlabel expansionpsychiatryantipsychoticM&A integration
Read the original article
Published by FiercePharma on September 21, 2026 2:36 PM